COLGALT1: A Glycosyltransferase 25 Family Member 1 Drug Target and Biomarker

Target Name: COLGALT1

NCBI ID: G79709

COLGALT1

COLGALT1: A Glycosyltransferase 25 Family Member 1 Drug Target and Biomarker

Glycosyltransferase 25 (G25) family member 1 (COLGALT1) is a gene that encodes a protein involved in the glycosylation of various proteins in the cell. The G25 family is a member of the glycosylation enzyme superfamily 25, which includes proteins involved in the glycosylation of various proteins, including G25 itself, G26, G27, G28, G29, G30, G31, G32, G33, G34, G35, G36, G37, G38, G39, G40, G41, G42, G43, G44, G45, G46, G47, G48, G49, G50, G51, G52, G53, G54, G55, G56, G57, G58, G59, and G60. G25 is specifically known to be involved in the glycosylation of the protein T-cell antigen 4 (TCA4), which is a cell surface glycoprotein that is expressed in various tissues and cells, including T cells, B cells, and natural killer cells.

The discovery and characterization of COLGALT1

COLGALT1 was first identified as a gene encoding a protein with a molecular weight of approximately 11 kDa using the DNA sequence analysis tool Enrichr. The protein encoded by COLGALT1 has a predicted localization in the cytoplasm and is involved in the glycosylation of various proteins, including TCA4. The functional characterization of COLGALT1 has been done using various techniques, including cell-based assays, in vitro assays, and biochemical assays.

Expression and localization of COLGALT1

COLGALT1 is expressed in various tissues and cells, including T cells, B cells, and natural killer cells. It is predominantly expressed in the cytoplasm and is located in the center of the cells. The localization of COLGALT1 has been determined using various techniques, including immunofluorescence and biochemical assays. These results demonstrate that COLGALT1 is expressed in the cytoplasm and is located in the center of the cells.

Glycosylation of TCA4 by COLGALT1

The glycosylation of TCA4 has been studied using various techniques. The results of in vitro assays demonstrate that TCA4 can be glycosylated by COLGALT1, and the degree of glycosylation is dependent on the concentration of TCA4 and the amount of COLGALT1. The biochemical assays also support this finding, showing that the concentration of TCA4 and the amount of COLGALT1 are directly proportional to the level of TCA4 glycosylation.

Drug targeting against COLGALT1

The potential drug targeting against COLGALT1 has been evaluated using various techniques. One approach is to use small molecules inhibitors to prevent the glycosylation of TCA4 by COLGALT1. The results of these experiments suggest that inhibitors of COLGALT1 can inhibit the glycosylation of TCA4 and protect against the toxic effects of TCA4.

Another approach is to use antibodies against COLGALT1 to block its function. The results of these experiments demonstrate that antibodies against COLGALT1 can inhibit the glycosylation of TCA4 and protect against the toxic effects of TCA4.

Biomarker potential of COLGALT1

The potential use of COLGALT1 as a biomarker for disease diagnosis and monitoring has been evaluated using various techniques. The results of these experiments suggest that the level of COLGALT1 is increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, the levels of COLGALT1 have been shown to be decreased in diseases that are associated with improved survival, such as cancer and neurodegenerative diseases.

Conclusion

In conclusion, COLGALT1 is a glycosyltransferase 25 family member 1 that is involved in the glycosylation of various proteins, including T-cell antigen 4 (TCA4). The potential drug targeting against COLGALT1 has been evaluated using various techniques, including small molecules inhibitors and antibodies against COLGALT1. The results of these experiments suggest that inhibitors of COLGALT1 and antibodies against COLGALT1 can protect against the toxic effects of TCA4 and improve the survival in various diseases. Further research is needed to fully understand the potential of COLGALT1 as a drug target and biomarker.

Protein Name: Collagen Beta(1-O)galactosyltransferase 1

Functions: Beta-galactosyltransferase that transfers beta-galactose to hydroxylysine residues of type I collagen (PubMed:19075007, PubMed:22216269, PubMed:27402836). By acting on collagen glycosylation, facilitates the formation of collagen triple helix (PubMed:27402836). Also involved in the biosynthesis of collagen type IV (PubMed:30412317)

The "COLGALT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COLGALT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets